Therapeutics Program

Red Bio leverages our foundational CRISPR-Cas9 technology to develop ‘Genomic cures’ targeting disease root causes. We address unmet medical needs through In Vivo platforms offering long-term efficacy from a single dose, and enhanced Ex Vivo cell therapies.
Advancing a robust pipeline, we deliver fundamental treatments to solve humanity’s greatest challenges: innovating medicines and extending life.

Ex Vivo gene editing maximizes safety by precisely modifying patient or donor cells outside the body before reinfusion. By combining living cell technologies with advanced gene editing techniques, we can deliver highly optimized, customized treatments for immune and rare diseases with maximum efficacy.
Using this platform, we are developing next-generation cell therapies to address unmet medical needs and provide safe, innovative options for treating intractable diseases.